ProCE Banner Activity

Application of the Latest Immuno-Oncology Developments to the Treatment of Urothelial Cancer

Learn how global experts leverage immuno-oncology therapies for optimal treatment of first-line and progressive urothelial cancer in this on-demand Webcast capturing a live CCO Webinar.

Released: October 15, 2020

Expiration: October 14, 2021

Share

Faculty

Thomas Powles

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Alain Ravaud

Alain Ravaud, MD, PhD

Professor of Medical Oncology
Bordeaux University
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Bordeaux, France

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Target Audience

This targeted program is designed to both inspire and instruct urologists, medical oncologists, and other healthcare providers caring for patients with urothelial cancer (UC) around the world and especially in Europe (Big 5 EU and Switzerland) and South America (Argentina). The identified target audience will benefit from this education by gaining the knowledge necessary to integrate the use of immune checkpoint inhibitors (ICI) into the treatment of advanced UC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, taking into consideration the available evidence and patient and disease characteristics
  • Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Discuss ongoing clinical trials investigating targeted systemic therapies and immune checkpoint inhibitor–based combinations for patients across the urothelial carcinoma disease spectrum
  • Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors

Faculty Disclosure

Primary Author

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomews Hospital (Barts Health NHS Trust)
London, United Kingdom

Thomas Powles, MBBS, MRCP, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; and other financial or material support from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.

Alain Ravaud, MD, PhD

Professor of Medical Oncology
Bordeaux University
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Bordeaux, France

Alain Ravaud, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Ipsen, Merck, MSD, Novartis, Pfizer, and Roche.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Goal


The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use of the current and evolving immuno-oncology–based standard of care, first-line treatments, and sequencing in the care of their patients with urothelial cancer.